The Covid-19 treatment studied in the paused trial was based on an effective antibody Lilly found in a recovered patient.
In a statement, the university confirmed the restart across all of its U.K. clinical trial sites after regulators gave the go-ahead following the pause on Sunday.
The study participant in late-stage testing reported symptoms consistent with transverse myelitis, a rare inflammation of the spinal cord, said company spokesman Matthew Kent.
The drug regulator's move comes after AstraZeneca, which is developing the vaccine candidate against COVID-19 with researchers of Oxford University
However, speaking to TNIE, B Suresh, Pro Chancellor of JSS AHER, said that so far, none among their 32 volunteers have reported any adverse reactions and all are doing fine.
India will continue Oxford vaccine trial, says Serum Institute after illness in volunteer pauses trial abroad
Serum Institute of India, under whose aegis the vaccine is to be being tried on 1,600 participants across 17 centres, said that trials in India will continue, irrespective of the latest development.
AstraZeneca is one of nine companies currently in late-stage Phase 3 trials for their vaccine candidates. In the US, the company began enrolling 30,000 volunteers across dozens of sites on August 31.
UNICEF to lead global procurement, supply of COVID vaccines; Australia to fund two potential candidates
UNICEF is the world's largest single vaccine buyer, procuring more than 2 billion doses of various vaccines annually for routine immunisation and outbreak response on behalf of nearly 100 countries.
The UK-based global biopharmaceutical company AstraZeneca is leading the trial as regulatory sponsor.
The ICMR will collect 100 samples from across the country for further study and look into modifications.
Three COVID-19 vaccine candidates, including two indigenous ones, are in different phases of development in India.
Prime Minister Scott Morrison said that Australia had reached a deal with Swedish-British pharmaceutical company AstraZeneca to receive the COVID-19 vaccine it is developing with Oxford University.
Production of the vaccine in Mexico and Argentina would allow for distribution throughout Latin America, except for Brazil, which had already reached its own agreement with the drug maker.
By end of August, between 4,000 to 5,000 people in Pune and Mumbai will be injected with the vaccine as part of trials that are scheduled to last over two months, SII said.
Adra Poonawalla told TNIE that the mass production of vaccine against the COVID-19 will start in the first quarter of next year while the human trials in India will start next month.